Market Insight - Cost of capital in royalty monetisation transactions
This article was originally published in Scrip
Executive Summary
In the current climate it is unsurprising that biopharmaceutical companies are tapping alternative sources of financing, including royalty monetisation for commercial products. Dr Ken Macleod, John Leone and Dr Walter Flamenbaum explain how investors weigh up risk when valuing such transactions.